COMMUNIQUÉS West-GlobeNewswire

Regeneration Biomedical Doses First Patient in a First-in-Human Phase I Clinical Trial of Stem Cell Therapy delivered directly into the brain of Patients with Alzheimer’s Disease
23/04/2024
Wnt-activated, autologous, expanded, adipose-derived stem cells administered directly into lateral ventricles of the brain via Ommaya reservoir implanted under the scalp to bypass blood brain barrier NEWPORT BEACH, [...]
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
23/04/2024
NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug [...]
Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma
23/04/2024
–Phase 1 trial in collaboration with Sant Joan de Déu-Barcelona Children’s Hospital (SJD) determined to have a positive outcome by the study Monitoring Committee– –Safety and clinical outcomes support the therapeutic [...]
Option Care Health Announces Financial Results for the First Quarter Ended March 31, 2024
23/04/2024
BANNOCKBURN, Ill., April 23, 2024 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion [...]
AVEROA Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of AVA1014 for Treating Complications Associated with Chronic Kidney Disease
23/04/2024
Grenoble, France, 23 rd April 2024 - Averoa, a biopharmaceutical company bringing innovative therapeutic solutions to people with renal diseases, announces the submission of a marketing authorisation application (MAA) [...]
CDR-Life to Present Tumor Targeting Capabilities of M-gager® Platform at the TCR-Based Therapies for Solid Tumors Summit
23/04/2024
ZÜRICH, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced a presentation on its proprietary antibody-major histocompatibility complex (MHC) technology for the development of highly specific T [...]
ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial
23/04/2024
A Novel Therapeutic Approach to Treatment using ITM-31 Garching/Munich, Munich and Münster, April 23, 2024 – The Departments of Neurosurgery and Nuclear Medicine at the University Hospital Münster, Helmholtz Munich, and [...]
Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 23 May 2024
23/04/2024
PRESS RELEASE REGULATED INFORMATION 23 April 2024, 07:00 am CET Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 23 May 2024 Publication of Annual Report 2023 Ghent, Belgium – [...]
AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting
23/04/2024
MILAN, Italy, April 23, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for [...]
Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 23 May 2024
23/04/2024
PRESS RELEASE REGULATED INFORMATION 23 April 2024, 07:00 am CET Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 23 May 2024 Publication of Annual Report 2023 Ghent, Belgium – [...]
Sequana Medical announces Annual General Meeting of Shareholders on 25 May 2023
23/04/2024
PRESS RELEASE REGULATED INFORMATION 23 April 2024, 07:00 am CET Publication of Annual Report 2023 Ghent, Belgium – 23 April 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), [...]
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
23/04/2024
Ad hoc announcement pursuant to Art. 53 LR Q1 net sales grew +11% (cc 1 , +10% USD) with core operating income up +22% (cc, +16% USD) Key growth drivers continued strong sales momentum including Entresto (+36% cc), [...]
Novartis, au premier trimestre: croissance à deux chiffres du chiffre d’affaires et expansion de la marge core; hausse des prévisions pour 2024
23/04/2024
Annonce événementielle au sens de l’art. 53 RC Résultats du premier trimestre (T1) Chiffre d’affaires net en hausse de +11% (tcc 1 , +10% USD) et du résultat opérationnel core, de +22% (tcc, +16% USD) Les moteurs clés [...]
Idorsia publishes an invitation to a bondholder meeting
23/04/2024
Ad hoc announcement pursuant to Art. 53 LR A bondholder meeting will take place on May 6, 2024, to vote on proposals to amend the terms of the outstanding convertible bonds maturing on July 17, 2024, including an [...]
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
23/04/2024
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to [...]
Communiqué de presse : L’étude de phase III LUNA 3 du rilzabrutinib pour le traitement de la thrombocytopénie immune a atteint son critère d’évaluation primaire
23/04/2024
L’étude de phase III LUNA 3 du rilzabrutinib pour le traitement de la thrombocytopénie immune a atteint son critère d’évaluation primaire Des données pivots de la première étude de phase III d’un BTKi dans la [...]
Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials
23/04/2024
ST. LOUIS, April 23, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has successfully enrolled and scanned patients in its SOLAR clinical trials: The first trial is SOLAR- [...]
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
22/04/2024
Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic hearing loss Additional presentations cover progress in novel [...]
Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
22/04/2024
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that six [...]

Pages